-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mercadon recalled its compound antibiotic product Zerbaxa because of microbial contamination, involving multiple batches, and Fessenyuskabi recalled 0.9 percent sodium chloride injections because some products were labeled Polish.
recall: Sterile drugs are at risk of microbial contamination Merck Sharp and Dohme Limited is recalling its compound antibiotic product Zerbaxa.
recall involves specific batches of Zerbaxa infusion concentrate powders in sizes of 1g / 0.5g.
: Recalled product: compound antibiotic Zerbaxa.
the most active ingredient is ceftolozane sulfate / tazobactam sodium, the active ingredient is the recall of the above batch because of the presence of Ralstonia pickettii contamination in recently produced batches.
this deviation, Mercedon initiates further investigations into the microbial quality of distributed products.
as a precautionary measure, Mercedon decided to recall the following commercially available batches: Figure: List of Recalled Product Batches Meshadon said the likelihood of contamination occurring in those batches was low.
even if these batches were present, the level of contamination would not be high and could lead to serious adverse health consequences.
is a Terrain-negative bacteria found in soil, rivers and lakes.
in water systems containing industrial plastics, they can be found in the form of biofilm bacteria.
to medical professionals to stop supplying the above batches immediately.
all inventory and return it to the supplier using a supplier-approved process.
patients with worsening symptoms or other suspected side effects during treatment with Zerbaxa should be reported through the Yellow Card Program (UK Adverse Reaction Reporting System).
, Fessenyuscabi: Labeling language error Fresenius Kabi Ltd is recalling 0.9 percent sodium chloride injections.
the ampoules in some small boxes are labeled Polish, and while this will not affect the entire batch, Fessenyuscabi decided to recall all packages in this batch as a precaution.
: Warning Notices from the UK's drug regulator, Fessen Yuscabi, says the small boxes in the batch are correct and have the correct instructions (in English).
drug ingredients and specifications meet UK licensing requirements, the batch used the wrong version of the ampoule label in the production process.
Faison Yuscabi decided to recall the following batches affected, and all returns will be replaced with other inventory batches.
image: Recall product batch information